Table 1 Baseline differences between trial eligible and ineligible UCC-SMART type 2 diabetes patients with established cardiovascular disease
Δ Eligible – ineligible (95% CI) | ||||
|---|---|---|---|---|
EMPA-REG OUTCOME | CANVAS | DECLARE-TIMI 58 | VERTIS-CV | |
Patient characteristics | ||||
Age (years) | − 0.2 (− 1.3, 0.8) | − 0.8 (− 1.8, 0.1) | − 2.4 (− 3.4, − 1.5) | − 1.0 (− 2.1, 0.2) |
Male (%) | − 5.5 (− 10.8, − 0.2) | − 4.8 (− 9.7, 0.2) | − 0.1 (− 4.7, 4.5) | − 5.3 (− 11.2, 0.7) |
Diabetes duration (years) | 1.5 (1.0, 2.5) | 2.0 (1.0, 2.5) | 1.0 (0.5, 2) | 2.0 (1.0, 3.0) |
Smoking current (%) | 3.3 (− 2.0, 8.6) | 5.7 (0.6, 10.7) | 6.7 (2.0, 11.4) | 3.9 (− 2.1, 9.9) |
History | ||||
Coronary artery disease (%) | 5.0 (− 0.5, 10.5) | 1.7 (− 3.6, 7) | 2.8 (− 2.2, 7.9) | 5.3 (− 0.8, 11.4) |
Cerebrovascular disease (%) | − 3.6 (− 8.9, 1.7) | − 3.6 (− 8.7, 1.4) | − 6.3 (− 11.2, − 1.5) | − 5.3 (− 11.2, 0.5) |
Peripheral artery disease (%) | 4.8 (− 0.2, 9.8) | 5.7 (1.0, 10.5) | 1.1 (− 3.3, 5.5) | 4.2 (− 1.5, 9.8) |
Medication | ||||
Total glucose lowering therapy (%) | 12.7 (8.2, 17.2) | 11.9 (7.5, 16.3) | 9.1 (4.7, 13.6) | 8.2 (3.0, 13.3) |
Glucose lowering agents (%) | 3.1 (− 2.5, 8.8) | 0.4 (− 5.0, 5.8) | 3.2 (− 1.9, 8.4) | − 3.0 (− 9.4, 3.5) |
Insulin (%) | 18.7 (13.2, 24.1) | 20.0 (14.9, 25.1) | 13.3 (8.7, 17.9) | 19.5 (13.2, 25.8) |
Antihypertensive therapy (%) | 2.7 (− 1.6, 7.0) | 0.6 (− 3.6, 4.8) | − 3.3 (− 7.3, 0.7) | 0.6 (− 4.3, 5.5) |
Lipid lowering therapy (%) | 0.4 (− 4.7, 5.6) | − 4.0 (− 9.0, 1.0) | − 1.2 (− 5.8, 3.5) | 2.8 (− 2.9, 8.5) |
Antithrombotic therapy (%) | 1.6 (− 2.5, 5.6) | − 3.4 (− 7.4, 0.7) | − 2.3 (− 6.0, 1.5) | 1.7 (− 2.8, 6.2) |
Physical examination | ||||
BMI (kg/m2) | 0.3 (− 0.2, 0.8) | 0.6 (0.1, 1.1) | 1.1 (0.7, 1.6) | 0.4 (− 0.2, 0.9) |
Systolic BP (mmHg) | 1.1 (− 1.3, 3.5) | 1.6 (− 0.7, 3.9) | − 5.8 (− 7.9, − 3.7) | − 11.4 (− 13.5, − 9.4) |
Diastolic BP (mmHg) | − 0.8 (− 2.1, 0.4) | − 0.2 (− 1.4, 1.1) | − 2.4 (− 3.6, − 1.3) | − 5.9 (− 7.0, − 4.7) |
Laboratory results | ||||
HbA1c (mmol/mol) | 12.1 (11.0, 13.2) | 16.2 (15.1, 17.3) | 12.1 (10.9, 13.3) | 11.9 (10.6, 13.1) |
HbA1c (%) | 1.1 (1.0, 1.2) | 1.5 (1.4, 1.6) | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.2) |
eGFR (CKD-EPI) (ml/min/1.73 m2) | 1.0 (− 1.2, 3.2) | 2.7 (0.6, 4.8) | 11.7 (9.7, 13.6) | 1.4 (− 1.1, 3.9) |
Total cholesterol (mmol/L) | 0.0 (− 0.1, 0.2) | 0.1 (0.0, 0.3) | − 0.1 (− 0.2, 0.03) | − 0.1 (− 0.2, 0.1) |
HDL-C (mmol/L) | 0.0 (− 0.1, 0.0) | − 0.1 (− 0.1, 0.0) | 0.03 (− 0.1, − 0.002) | − 0.04 (− 0.08, − 0.003) |
LDL-C (mmol/L) | 0.0 (− 0.1, 0.1) | 0.0 (− 0.1, 0.2) | − 0.2 (− 0.3, − 0.1) | − 0.04 (− 0.2, 0.1) |
Triglycerides (mmol/L) | 0.1 (0.0, 0.2) | 0.2 (0.1, 0.3) | 0.1 (0.01, 0.2) | 0.1 (− 0.1, 0.2) |